Patent · US Active

Secernin-1 as a marker for cancer

US9518990B2 · kind B2 · utility

2Cited by

0References

4Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Norbert Wild · Geretsried, DE
Marie-Luise Hagmann · Penzberg, DE
Johann Karl · Peißenberg, DE
Julia Riedlinger · Ottobrunn, DE
Markus Roessler · Germering, DE
Michael Tacke · Munich, DE

Key dates

Filing date	Oct 13, 2011
Grant date	Dec 13, 2016
Priority date	—
Expiry date	Jan 20, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/57484
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.